Halozyme Therapeutics (HALO) Total Non-Current Liabilities (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Total Non-Current Liabilities data on file, last reported at $2.3 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $2.3 billion, up 41.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 41.55% YoY), and the FY2025 annual result was $2.4 billion, up 43.63% from the prior year.
• Total Non-Current Liabilities fell to $2.3 billion in Q1 2026 per HALO's latest filing, from $2.4 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.4 billion in Q4 2025 and troughed at $901.8 million in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 95.33% in 2022, then retreated 6.73% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $1.7 billion in 2022, then decreased by 2.69% to $1.6 billion in 2023, then advanced by 2.06% to $1.6 billion in 2024, then jumped by 43.63% to $2.4 billion in 2025, then declined by 0.68% to $2.3 billion in 2026.
• Business Quant data shows HALO's Total Non-Current Liabilities at $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $1.6 billion in Q3 2025.